Cartesian Therapeutics (RNAC) Receivables - Net (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Receivables - Net data on file, last reported at $261000.0 in Q1 2026.

• Receivables - Net for Q1 2026 came in at $261000.0, down 85.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $261000.0 (down 85.21% YoY), and the FY2025 annual result was $1.1 million, up 27.87% from the prior year.
• Receivables - Net retreated to $261000.0 in Q1 2026 per RNAC's latest filing, from $1.1 million in the prior quarter.
• Over five years, Receivables - Net peaked at $32.0 million in Q2 2024 and troughed at $261000.0 in Q1 2026.
• A 5-year average of $6.6 million and a median of $4.9 million in 2023 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net jumped 494.97% in 2024, then tumbled 98.9% in 2025.
• A 5-year view of Receivables - Net shows it stood at $6.6 million in 2022, then declined by 11.01% to $5.9 million in 2023, then slumped by 85.14% to $872000.0 in 2024, then grew by 27.87% to $1.1 million in 2025, then tumbled by 76.59% to $261000.0 in 2026.
• Business Quant data shows RNAC's Receivables - Net at $261000.0 in Q1 2026, $1.1 million in Q4 2025, and $722000.0 in Q3 2025.